FDA Approves Vyalev for Advanced Parkinson Disease

Follow Drugslib on

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

TUESDAY, Oct. 22, 2024 -- The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson disease (PD).

Vyalev is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced PD and allows for personalized dosing throughout the day based on individual needs. The manufacturer, AbbVie, says coverage for Medicare patients is expected in the second half of 2025.

The approval was supported by a pivotal phase 3, 12-week study that compared the efficacy of a continuous subcutaneous infusion of Vyalev to oral immediate-release carbidopa/levodopa (CD/LD IR), as well as a 52-week, open-label study that evaluated the long-term safety and efficacy of Vyalev. The pivotal study showed patients receiving Vyalev had superior improvement in motor fluctuations, with increased "on" time without troublesome dyskinesia and decreased "off" time compared with oral CD/LD IR. The majority of adverse reactions with Vyalev were nonserious and mild or moderate in severity, including most frequently (≥10 percent and greater than CD/LD IR incidence) infusion site events, hallucinations, and dyskinesia.

"Due to the progressive nature of the disease, oral medications are eventually no longer as effective at motor symptom control and surgical treatment may be required," Robert A. Hauser, M.D., from the Parkinson's and Movement Disorder Center at the University of South Florida in Tampa, said in a statement. "This new, nonsurgical regimen provides continuous delivery of levodopa morning, day, and night."

Approval of Vyalev was granted to AbbVie.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-23 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords